Kailera Therapeutics, Inc.

We are a clinical-stage biopharmaceutical company with a clear and determined mission: to develop a broad and advanced therapeutic pipeline that offers differentiated treatment options for individuals struggling with obesity and related conditions. At Kailera, we are driven by a commitment to scientific and clinical excellence, placing data and rigorous research at the very core of everything we do. Our experienced leadership team carries a significant track record of building innovative companies that have successfully delivered paradigm-shifting technologies to the world. We are poised to leverage this expertise to ensure our breakthrough therapies reach the patients who need them most, empowering them to transform their lives and elevate their overall health.

Our robust pipeline includes a diverse range of clinical and preclinical programs, featuring injectable peptides, oral peptides, and an oral small molecule. We believe in a multi-faceted approach to treatment, which is why our portfolio is diversified across various mechanisms of action and both injectable and oral delivery methods. This strategy allows us to address the complex nature of chronic weight management from multiple angles. Our lead program, KAI-9531, is an injectable GLP-1/GIP receptor dual agonist that has already shown compelling results in Phase 2 trials in China for both obesity and diabetes. Beyond this, we are actively advancing other promising candidates, including KAI-7535, a clinical-stage oral small molecule GLP-1 receptor agonist. We are backed by top-tier healthcare investors who share our vision and are dedicated to helping us develop therapies that give people the power to take control of their health and significantly improve their quality of life. We are bold, authentic, and deeply committed to fostering an inclusive and collaborative culture where the most talented individuals can thrive and contribute to our mission.